anti-doping is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-06-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
A common misconception is that cardarine has been proven safe for human use. In reality, human clinical data are limited, and long-term animal studies have raised concerns about cancer. Another misconception is that it is a supplement or vitamin-like compound. It is a synthetic research chemical with no approved medical indication. Scientific discussion often focuses on its mechanism and detection rather than therapeutic use. Regulatory and anti-doping literature treats it primarily as a prohibited substance.
Cardarine is explicitly prohibited by the World Anti-Doping Agency under the class of PPARδ agonists. Its presence in urine or blood samples can be detected using mass spectrometry-based methods, often liquid chromatography-tandem mass spectrometry. Athletes who test positive may face sanctions, including bans from competition. The compound is also regulated as a prescription-only or unapproved drug in many countries. Enforcement varies by jurisdiction, and some regions treat it as a controlled substance. Online sales may occur despite these restrictions, creating quality and legal risks.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Prohibited in sport | Listed by WADA as a PPARδ agonist. |
| Typical detection matrix | Urine | Most common sample for anti-doping analysis. |
| Common analytical method | LC-MS/MS | Liquid chromatography-tandem mass spectrometry. |
| Common synonyms | GW501516, GSK-516, endurobol | Names found in research and fitness contexts. |
| Typical detection window | Variable | Depends on dose, route, and individual metabolism. |
Clinical development stopped after rodent studies showed tumors at multiple sites. Whether those findings predict human cancer risk remains an open question, but they led sponsors to discontinue programs. Human safety data are limited to small, short-term studies that were not designed to assess cancer risk. Reported effects in those studies included changes in blood lipids, but the evidence is insufficient for medical use. Long-term consequences of nonmedical use are not well characterized. Questions about dose, duration, and individual susceptibility remain unresolved.
Cardarine is a common name for GW501516, an investigational compound developed in the 1990s for metabolic conditions. It acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in lipid and energy metabolism. The compound is frequently mislabeled as a selective androgen receptor modulator, or SARM, but its molecular target is different. GW501516 reached early clinical testing before development was discontinued. It has no approved therapeutic use in any country. The name cardarine is not a formal international nonproprietary name.
Regulatory treatment varies, but cardarine is not approved as a medicine. Sports authorities list GW501516 as a prohibited substance, and it is banned at all times under the World Anti-Doping Agency code. Many countries restrict sales for human consumption, while online vendors market it as a research chemical. Such products may lack purity data, and their actual contents can differ from the label. Purchasing or possessing cardarine may carry legal consequences depending on jurisdiction. The compound is not a dietary supplement ingredient in regulated markets.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Handling and quality assessment of cardarine reference material follow general laboratory practices for poorly characterized compounds. It typically appears as a white to off-white powder and is sparingly soluble in water but soluble in organic solvents such as dimethyl sulfoxide and ethanol. Storage recommendations usually specify a cool, dry, dark place, with long-term storage at low temperature and desiccation. Purity may be checked by high-performance liquid chromatography with ultraviolet detection, while identity is confirmed by mass spectrometry and nuclear magnetic resonance. No pharmacopeial monograph exists, so reported purity and stability depend on the supplier’s methods.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
Anti-doping laboratories identify GW501516 and related metabolites using liquid chromatography coupled with tandem mass spectrometry. Urine is the most common matrix, though blood and dried blood spots may also be analyzed. The method targets the parent compound and phase I and phase II metabolites, which extend the detection window. Because the substance is prohibited at all times, athletes can be tested outside competition. Detection limits and windows depend on the assay, sample type, and individual metabolism.
Cardarine is frequently described as a fat-burning or endurance-enhancing supplement, but these claims exceed the available evidence. The compound is not a hormone, steroid, or selective androgen receptor modulator. Research articles discuss it as a tool compound for studying PPARδ biology, while anti-doping literature focuses on its abuse and detection. Quality of unapproved products is uncertain, and independent analyses have found impurities or incorrect labeling. Open questions include whether human cancer risk resembles that seen in rodents and how often non-athletes use the substance.
Cardarine has no approved therapeutic indication and is not marketed as a medicine. The World Anti-Doping Agency lists GW501516 as a prohibited substance at all times, covering both in-competition and out-of-competition periods. National laws vary: some countries treat it as an unapproved drug subject to import controls, while others have specific restrictions on sale for human consumption. It is often sold as a research chemical, a label that does not imply safety or legality. Enforcement actions have targeted online vendors and shipments.
This regulates the reaction catalyzing fructose 2,6-bisphosphate (a potent activator of phosphofructokinase-1, the enzyme that is the primary regulatory step of glycolysis) by slowing the rate of its formation, thereby inhibiting the flux of the glycolysis pathway and allowing gluconeogenesis to predominate. This process is reversible in the absence of glucagon (and thus, the presence of insulin). Glucagon stimulation of PKA inactivates the glycolytic enzyme pyruvate kinase, inactivates glycogen synthase, and activates hormone-sensitive lipase, which catabolizes glycerides into glycerol and free fatty acid(s), in hepatocytes. Glucagon also inactivates acetyl-CoA carboxylase (ACC), which creates malonyl-CoA from acetyl-CoA, through cAMP-dependent and/or cAMP-independent kinases. Malonyl-CoA is a product formed by ACC during denovo synthesis and an allosteric inhibitor of carnitine palmitoyltransferase I (CPT1), a mitochondrial enzyme important for bringing fatty acids into the intermembrane space of the mitochondria for β-oxidation. Glucagon decreases malonyl-CoA through inhibition of acetyl-CoA carboxylase and through reduced glycolysis through its aforementioned reduction in Fructose 2,6-bisphosphate. Thus, reduction in malonyl-CoA is a common regulator for the increased fatty acid metabolism effects of glucagon.
Zinc has an electron configuration of [Ar]4s23d10 and is a member of the group 12 of the periodic table. It is a moderately reactive metal and strong reducing agent; in the reactivity series it is comparable to manganese. The surface of the pure metal tarnishes quickly, eventually forming a protective passivating layer of the basic zinc carbonate, Zn5(OH)6(CO3)2, by reaction with atmospheric carbon dioxide. Zinc burns in air with a bright bluish-green flame, giving off fumes of zinc oxide. Zinc reacts readily with acids, alkalis and other non-metals. Extremely pure zinc reacts only slowly at room temperature with acids. Strong acids, such as hydrochloric or sulfuric acid, can remove the passivating layer and the subsequent reaction with the acid releases hydrogen gas. Zinc chemistry resembles that of the late first-row transition metals, nickel and copper, as well as certain main-group elements. Almost all zinc compounds have the element in the +2 oxidation state. When Zn2+ compounds form, the outer shell s electrons are lost, yielding a bare zinc ion with the electronic configuration [Ar]3d10. The filled interior d shell generally does not participate in bonding, producing diamagnetic and mostly colorless compounds. In aqueous solution an octahedral complex, [Zn(H2O)6]2+ is the predominant species. The ionic radii of zinc and magnesium happen to be nearly identical.
=== Cardiac examination of congenital muscular dystrophies === The cardiac manifestations of CMD vary greatly. They can range from non-existent or mild to severe and fatal cardiac involvement. Generally, cardiac abnormalities in CMD can manifest in dilated cardiomyopathy, systolic dysfunction, hypertrophic cardiomyopathy, myocardial fibrosis or fatal ventricular arrhythmias.
Climate change is projected to raise average temperatures in Portugal by as much as 3–4 °C (37.4–39.2 °F) by 2100 relative to the 1990s–2010s average, with impacts in water, ecosystem, agriculture, health, and security.
Glutaredoxin 2 (GLRX2) is an enzyme that in humans, is encoded by the GLRX2 gene. GLRX2, also known as GRX2, is a glutaredoxin family protein and a thiol-disulfide oxidoreductase that maintains cellular thiol homeostasis. This gene consists of four exons and three introns, spanned 10 kilobase pairs, and localized to chromosome 1q31.2–31.3. Alternative splicing of GLRX2 leads to three isoforms of Grx2. One isoform, Grx2a, localizes to the mitochondria, is ubiquitously expressed in tissues (e.g. heart, skeletal muscle, kidney, and liver), regulates mitochondrial redox homeostasis, and protects cells against oxidative stress. Isoforms Grx2b and Grx2c, both localized to the nucleus and cytosol, are expressed only in testes and cancer cell lines and facilitate cellular differentiation and transformation, potentially inducing tumor progression.
Sources: en.wikipedia.org
With the deal, Whedon contributed creatively to all of the Phase Two films and also developed Agents of S.H.I.E.L.D., the first television series set in the MCU. In April 2017, Guardians of the Galaxy (2014) and Guardians of the Galaxy Vol. 2 (2017) writer and director James Gunn revealed that he would be working with Marvel to help plan future stories for the Guardians of the Galaxy characters and the wider "Marvel Cosmic Universe", although Gunn became the co-CEO of DC Studios in November 2022 and signed a four-year deal to work exclusively on DC Comics-based projects. For Phase Three, there was a large amount of collaboration between the filmmakers of the individual character films and the filmmakers of the crossover films Avengers: Infinity War and Avengers: Endgame, which were directed by the Russo brothers and written by Christopher Markus and Stephen McFeely. This was to ensure their storytelling aligned for the Infinity Saga's culmination. Marvel Studios began contracting their actors for multiple films, including signing actor Samuel L. Jackson to a then-unprecedented nine-film contract. Feige said the studio had all actors sign contracts for multiple films, with the normal number being for three or more, while the nine- or twelve-film deals were rare. The actors' contracts also feature clauses that allow Marvel to use up to three minutes of an actor's performance from one film in another, which Marvel describes as "bridging material".
== Society and culture == Chlordiazepoxide is the drug referenced in the Netflix series "The Queen's Gambit," under the commercial name Librium. It also appears prominently in the HBO series "The Pitt." In “Infinite Jest”, by David Foster Wallace, a nurse “negotiated a trade of shoes for Librium” with the character Tiny Ewell. In the first episode of Yes, Minister, Jim Hacker tells his wife Annie to take a Librium when she couldn't find a cigarette.
Sotagliflozin, sold under the brand name Inpefa among others, is a medication used to reduce the risk of death due to heart failure. It is an inhibitor of sodium-glucose cotransporter 1 and 2 (SGLT1/SGLT2 inhibitor). It is taken by mouth. The most common adverse reactions include urinary tract infection, volume depletion, diarrhea, and hypoglycemia.. In additions, concerns aboout diabetic ketoacidosis led to the USA'S Food & Drug Administration not approving sotagliflozin along with insulin for the emergency treatment of hyperglycemia. Similar concerns led to the drug's later withdrawal from the European Union. Sotagliflozin was approved for medical use in the European Union in April 2019, as Zynquista, for the treatment for type 1 diabetes, and in the United States in May 2023, to reduce the risk of death due to heart failure. The marketing authorization for sotagliflozin was withdrawn in the EU in August 2022, at the request of the marketing-authorization holder.
==== 2009 ==== In January 2009, Krasnaya Zvezda published an interview with Father Mikhail, the Orthodox priest, who said: "I attended military exercise "Kavkaz-2008" in South Ossetia, where our paratroopers worked out the skills of combat in the mountains. Unfortunately, those skills became useful too soon..." In late January 2009, Russian sergeant Aleksandr Glukhov ran away from Akhalgori District and requested a political asylum in Tbilisi. He had served in the 693rd regiment and he declared that he was deployed to South Ossetia in July 2008. In May 2009, Rossiyskaya Gazeta reported that hero of Russia, Denis Vetchinov, who died in South Ossetia, left the base of the Motor Rifle Division in Vladikavkaz for Tskhinvali on the early morning of 7 August 2008. In June 2009, Russian General Vyacheslav Borisov told Echo of Moscow in an interview: "I headed the South Ossetian and the Georgian directions. You know, we even regularly hold exercises in those areas. And our troops had full practice by holding exercises one week before right there in the same place. And we had only concluded and went." In July 2009, Russian journalist Ella Polyakova wrote that some Russian soldiers had told her that they arrived in South Ossetia on 4 August 2008, while their records claimed that they were stationed in North Ossetia. In July 2009, Russian blogger published an interview with soldier Maksim Belyaev, who said: "Our combined battalion of peacekeepers was stationed in North Ossetia. We should have replaced in August another battalion of the peacekeeping mission, located in Tskhinvali.
=== In popular culture === Invented in 1949, and marketed and sold commercially by Hasbro in 1952, Mr. Potato Head is an American toy that consists of a plastic potato and attachable plastic parts, such as ears and eyes, to make a face. It was the first toy ever advertised on television. In the 2015 science fiction film The Martian, the protagonist, a stranded astronaut and botanist named Mark Watney, cultivates potatoes on Mars using Martian soil fertilized with frozen feces.
Sources: en.wikipedia.org
PMID 17482543. S2CID 4661723. Bieganowski, P; Brenner, C (2004). "Discoveries of Nicotinamide Riboside as a Nutrient and Conserved NRK Genes Establish a Preiss-Handler Independent Route to NAD+ in Fungi and Humans". Cell. 117 (4): 495–502. doi:10.1016/S0092-8674(04)00416-7. PMID 15137942. S2CID 4642295. Brenner, C; Duggan, D, eds. (2004). Oncogenomics: Molecular approaches to cancer. Hoboken, N.J.: Wiley-Liss. ISBN 0-471-22592-4. Trapasso, F; Krakowiak, A; Cesari, R; Arkles, J; Yendamuri, S; Ishii, H; Vecchione, A; Kuroki, T; Bieganowski, P; Pace, HC; Huebner, K; Croce, CM; Brenner, C; et al. (18 February 2003). "Designed FHIT alleles establish that Fhit-induced apoptosis in cancer cells is limited by substrate binding". Proceedings of the National Academy of Sciences of the United States of America. 100 (4): 1592–7. Bibcode:2003PNAS..100.1592T. doi:10.1073/pnas.0437915100. PMC 149877. PMID 12574506. Draganescu, A; Hodawadekar, SC; Gee, KR; Brenner, C (2000). "Fhit-Nucleotide Specificity Probed with Novel Fluorescent and Fluorogenic Substrates". J. Biol. Chem. 275 (7): 4555–4560. doi:10.1074/jbc.275.7.4555. PMC 2556043. PMID 10671479. Brenner, C; Fuller, RS (1992). "Structural and Enzymatic Characterization of a Purified Prohormone-Processing Enzyme: Secreted, Soluble Kex2 Protease". Proc. Natl. Acad. Sci. 89 (3): 922–926. Bibcode:1992PNAS...89..922B. doi:10.1073/pnas.89.3.922. PMC 48357. PMID 1736307.
==== Second Schleswig War ==== In 1863, conflict broke out again when Frederick VII died without legitimate issue. According to the order of succession of Denmark and Schleswig, the crowns of both Denmark and Schleswig would pass to Duke Christian of Glücksburg, who became Christian IX. The transmission of the duchy of Holstein to the head of the (German-oriented) branch of the Danish royal family, the House of Augustenborg, was more controversial. The separation of the two duchies was challenged by the Augustenborg heir, who claimed, as in 1848, to be the rightful heir of both Schleswig and Holstein. A common constitution for Denmark and Schleswig was promulgated in November 1863, which was a breach of the 1852 London Protocol. This left Denmark politically isolated and led to the Second Schleswig War, with Prussia and Austria invading once again. Denmark achieved some initial victories at the Battles of Mysunde, and Sankelmark, but these successes were short-lived. The Austrians defeated the Danes at the Königshügel and Vejle. However, it was the Prussians who decided the war by decisively winning the pivotal Battles of Dybbøl and Als. British attempts to mediate in the London Conference of 1864 failed. With the peace Treaty of Vienna (1864), Denmark was forced to cede Schleswig, Holstein, and Lauenburg to Prussia and Austria. Prussia wished to annex the conquered territories, but Austria insisted they be held as condominiums.
In November 1944, the division and several attached units were redesignated as Panzerkorps Großdeutschland. By March 1945, the Panzer Grenadier Division Großdeutschland had been reduced to around 4,000 men after the Battle of Memel. It had only one Sturmgeschütz III self-propelled gun, one Panzer IV, five Panthers, and six Tiger Is by 15 March 1945. By 25 April, the division was engaged in heavy fighting in the battles around Pillau. Eight hundred men of the division were evacuated on ferries via the Baltic Sea and surrendered to British forces in Schleswig-Holstein on 9 May. The rest were either killed or captured during the fighting in Pillau or surrendered to Soviet forces on 9 May on the Vistula spit.
As in the 2023 election, the electoral system followed that of the 2021 amendment of the 2017 constitution. The 500 members of the House of Representatives were elected by parallel voting. 400 seats were elected from single-member constituencies by first-past-the-post voting and 100 seats by proportional representation. Voters cast separate ballots for the two sets of seats. The 100 party-list seats were distributed under the "100 divisor" formula, restored in 2022 after parliament failed to finalise a rival draft within its 180-day deadline. The national party-list vote is divided by 100 to give a quota; each party takes one seat for every whole quota it has won, and the seats still unfilled go to the parties with the largest fractional remainders. List seats are awarded on top of constituency seats rather than in compensation for them, so a party that sweeps the constituencies keeps its full proportional entitlement as well. Writing shortly before the system was first used, Napon Jatusripitak of the ISEAS–Yusof Ishak Institute observed that cutting the number of list seats from 150 to 100 raised the share of the vote needed to win one and allowed larger parties to take a higher proportion of seats than of votes. At the 2026 election the 35,030,579 valid party-list votes produced a quota of 350,306.
Sources: en.wikipedia.org
Yes, WADA prohibits cardarine as a PPARδ agonist. It appears on the prohibited list and can be detected in urine or blood. Athletes using it risk sanctions.
Detection usually uses liquid chromatography-tandem mass spectrometry after sample cleanup. Laboratories look for the parent compound or metabolites. The method requires validated reference standards and controls.
Legality varies by country. In many places it is an unapproved drug and cannot be legally sold for human consumption. Purchasing from online vendors carries legal and quality risks.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.